Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118371520> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3118371520 endingPage "S343" @default.
- W3118371520 startingPage "S335" @default.
- W3118371520 abstract "The first tablet formulation of a glucagon-like peptide-1 receptor agonist(GLP-1RA), oral semaglutide, was approved in September 2019 for the treatment of adults with type 2 diabetes (T2D). This article reviews data from the PIONEER phase 3a clinical trial program, which assessed the efficacy and safety of oral semaglutide in more than 9500 patients at different stages on the disease trajectory (mean diabetes duration,3.5-15 years) and on a range of background treatment regimens(monotherapy, added to 1 or 2 oral glucose-lowering agents, or added to insulin). The studies compared oral semaglutide (doses of 3 mg, 7 mg, or14 mg) with placebo, and selected commonly used glucose-lowering agents (empagliflozin 25 mg, sitagliptin 100 mg, or liraglutide 1.8mg). Across the studies, oral semaglutide provided greater glycated hemoglobin (A1C) reductions than placebo, empagliflozin, or sitagliptinat 26 weeks, and similar A1C reductions as liraglutide. The proportion of patients achieving the A1C level recommended by the American Diabetes Association of less than 7.0% (53 mmol/mol) was greater with oral semaglutide (7 mg, 42%-69%; 14 mg, 55%-77%) than placebo (7%-31%)and active comparators (25%-62%), with durable target achievement. Oral semaglutide was associated with similar reductions in body weight as empagliflozin and greater reductions than placebo, sitagliptin, or liraglutide. Oral semaglutide was also efficacious in patients with T2D and moderate renal impairment. These findings indicate that oral semaglutide presents a valuable option for treating patients with T2D in a managed care setting, with the potential to expand the number of patients benefiting from GLP‑1RAs." @default.
- W3118371520 created "2021-01-18" @default.
- W3118371520 date "2020-12-01" @default.
- W3118371520 modified "2023-10-10" @default.
- W3118371520 title "Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care" @default.
- W3118371520 doi "https://doi.org/10.37765/ajmc.2020.88554" @default.
- W3118371520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33439582" @default.
- W3118371520 hasPublicationYear "2020" @default.
- W3118371520 type Work @default.
- W3118371520 sameAs 3118371520 @default.
- W3118371520 citedByCount "10" @default.
- W3118371520 countsByYear W31183715202021 @default.
- W3118371520 countsByYear W31183715202022 @default.
- W3118371520 countsByYear W31183715202023 @default.
- W3118371520 crossrefType "journal-article" @default.
- W3118371520 hasConcept C126322002 @default.
- W3118371520 hasConcept C134018914 @default.
- W3118371520 hasConcept C142724271 @default.
- W3118371520 hasConcept C204787440 @default.
- W3118371520 hasConcept C27081682 @default.
- W3118371520 hasConcept C2775887513 @default.
- W3118371520 hasConcept C2777180221 @default.
- W3118371520 hasConcept C2777538456 @default.
- W3118371520 hasConcept C2779284873 @default.
- W3118371520 hasConcept C2779829264 @default.
- W3118371520 hasConcept C2781308992 @default.
- W3118371520 hasConcept C2909862629 @default.
- W3118371520 hasConcept C2910260750 @default.
- W3118371520 hasConcept C555293320 @default.
- W3118371520 hasConcept C71924100 @default.
- W3118371520 hasConcept C98274493 @default.
- W3118371520 hasConceptScore W3118371520C126322002 @default.
- W3118371520 hasConceptScore W3118371520C134018914 @default.
- W3118371520 hasConceptScore W3118371520C142724271 @default.
- W3118371520 hasConceptScore W3118371520C204787440 @default.
- W3118371520 hasConceptScore W3118371520C27081682 @default.
- W3118371520 hasConceptScore W3118371520C2775887513 @default.
- W3118371520 hasConceptScore W3118371520C2777180221 @default.
- W3118371520 hasConceptScore W3118371520C2777538456 @default.
- W3118371520 hasConceptScore W3118371520C2779284873 @default.
- W3118371520 hasConceptScore W3118371520C2779829264 @default.
- W3118371520 hasConceptScore W3118371520C2781308992 @default.
- W3118371520 hasConceptScore W3118371520C2909862629 @default.
- W3118371520 hasConceptScore W3118371520C2910260750 @default.
- W3118371520 hasConceptScore W3118371520C555293320 @default.
- W3118371520 hasConceptScore W3118371520C71924100 @default.
- W3118371520 hasConceptScore W3118371520C98274493 @default.
- W3118371520 hasIssue "Suppl 16" @default.
- W3118371520 hasLocation W31183715201 @default.
- W3118371520 hasLocation W31183715202 @default.
- W3118371520 hasOpenAccess W3118371520 @default.
- W3118371520 hasPrimaryLocation W31183715201 @default.
- W3118371520 hasRelatedWork W2567011734 @default.
- W3118371520 hasRelatedWork W2606536757 @default.
- W3118371520 hasRelatedWork W2807279220 @default.
- W3118371520 hasRelatedWork W2904775589 @default.
- W3118371520 hasRelatedWork W2948380809 @default.
- W3118371520 hasRelatedWork W2981518229 @default.
- W3118371520 hasRelatedWork W2997605969 @default.
- W3118371520 hasRelatedWork W3066769783 @default.
- W3118371520 hasRelatedWork W3118371520 @default.
- W3118371520 hasRelatedWork W4281477563 @default.
- W3118371520 hasVolume "26" @default.
- W3118371520 isParatext "false" @default.
- W3118371520 isRetracted "false" @default.
- W3118371520 magId "3118371520" @default.
- W3118371520 workType "article" @default.